about
Main roads to melanomaFunction, regulation and pathological roles of the Gab/DOS docking proteinsDistinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallingRecurrent BRAF mutations in Langerhans cell histiocytosisTherapeutic Implications of Targeting AKT Signaling in MelanomaBRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapiesMAPK pathway activation in pilocytic astrocytomaCurrent and future trials of targeted therapies in cutaneous melanomaDisruptive chemicals, senescence and immortalityTherapeutic targeting of replicative immortalityPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Genetics of melanocytic neviCell(s) of Origin of Langerhans Cell HistiocytosisRegistered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivationOncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumorsAn in silico study of the molecular basis of B-RAF activation and conformational stability.Polyclonality of BRAF mutations in acquired melanocytic nevi.Histone variants: emerging players in cancer biology.Gene expression changes with age in skin, adipose tissue, blood and brain.FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3.Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironmentThe essence of senescence.Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling.Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.Stage-specific prognostic biomarkers in melanomaBRAF V600E mutational status in bile duct adenomas and hamartomas.Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells.Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions.Mutational status of naevus-associated melanomas.Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma.c-Myc modulation: a key role in melanoma drug response.Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patientsBRAF mutation in papillary thyroid carcinoma
P2860
Q21245465-76F62AD9-D057-405E-B655-AFD624F73F65Q21245511-A992B619-0C9C-4A78-8E60-EFB54A3AB5F0Q24314807-823B355B-7AAC-4D5A-A846-73F95DA8AFD1Q24594344-3EC6F019-B589-4AB1-A5AD-5FB48DDC40A4Q24631438-C7FFEE50-2E50-4600-BBF1-F667A70647BBQ26772276-4C1AAB03-2E2F-4C18-AE46-50CF44607C8EQ27006028-156ABB0A-7B21-4B7C-90AD-C756F02880B7Q27022355-EEC2860D-2547-47AE-B866-89A541662510Q27026235-8B2F62EC-9FCD-4ECA-A12C-F4B78CFB0FFBQ27027457-99470649-D6B4-477A-9DF2-E2D6D7AA68F9Q27853224-C851B405-9624-4362-B674-E1B279EF1636Q28085036-C35A6A04-98CA-46B4-83C3-63C20FBC7732Q28087231-20817C1A-4E47-4AE2-BE1D-4A39499F5BB1Q28601717-248F13BA-BE8D-4FD2-937F-E1B794BF1BF7Q28756117-0F7D0EB7-EEDA-4F5D-9BB3-9A015AB8E746Q33485591-47EE6DA7-7571-4BCB-9614-01A8AB2BA8A5Q33502965-E40F7695-B950-4F1B-8BCA-FB24BCCCE13AQ33630867-622CCC27-AC6B-4268-8693-992E6E31DACCQ33742819-E9E51E2D-9276-4923-9845-7E21A2E7DF5BQ33767083-C3F10754-83CE-4D82-9F2D-04666AC7B75AQ33772206-B0DE193D-C1E8-4747-A660-E30D1A80E570Q33820241-031EDC4E-DFA2-42A8-9A03-C4E49CB71340Q33971905-562AAD28-DD27-4390-BFD5-2FC1B4715BAEQ33988695-8F2C45BD-7A70-4BA2-8D89-55F37E6FF36DQ34132964-61F09C1A-7B1C-4B62-A5CF-65D5B1F8A595Q34137706-2A345D6C-7AAF-4701-82DD-9CA117800CA7Q34288983-3AC5B1E3-C978-4B4B-8D8E-9A04A38F8E0CQ34289063-4B6E3F7F-1E74-4F41-B256-10F0D46EC93EQ34388261-3855504D-0167-4988-BC9C-C68872075F70Q34612281-2194D2C0-BA35-463D-A271-0DAB68406C1DQ35144523-3A88102B-2844-4B5A-BC99-582206BE3222Q35551970-A6C1B759-AC45-4D18-A559-622800E8D159Q35565384-BF1D171B-0EEE-4842-9153-2932AFAC06D0Q35865238-57756FF4-02AE-470A-9AF9-87EC0FE83E52Q36090294-EF45457F-6A90-4D45-8B8A-1A95AA5CC3CCQ36095004-1C0DD4E1-7811-45E0-A370-774A3C34E00BQ36142551-8F7CD2C5-4051-4049-9314-FF1F6EB311FBQ36213103-C4CCE71D-E997-45DB-B34B-DB251AFEA336Q36216904-FAFBA2DC-43D0-4177-BFE3-9436E56CECE6Q36238518-9EA33B88-A099-4E44-87DB-9FB677B19FEE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
BRAF(E600) in benign and malignant human tumours.
@en
type
label
BRAF(E600) in benign and malignant human tumours.
@en
prefLabel
BRAF(E600) in benign and malignant human tumours.
@en
P2093
P2860
P356
P1433
P1476
BRAF(E600) in benign and malignant human tumours.
@en
P2093
Michaloglou C
Vredeveld LC
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210704
P407
P577
2007-08-27T00:00:00Z